Nucleus RadioPharma
Rochester, MN
Program data pending ClinicalTrials.gov matching
57.5
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (10)
○ EMA GMP
○ MHRA GMP
Quick Facts: Nucleus RadioPharma
- Signal Score
- 57.5/100
- Quality Compliance
- Assessment pending
- Headquarters
- Rochester, MN
- Modalities
- Radiopharmaceutical CDMO (end-to-end), Clinical and commercial supply chain for targeted radiotherapies, Isotope sourcing and supply agreements
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Nucleus RadioPharma
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesRadiopharmaceutical CDMO (end-to-end), Clinical and commercial supply chain for targeted radiotherapies, Isotope sourcing and supply agreements
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
55.0
Manufacturing site information being gathered
Modalities: Radiopharmaceutical CDMO (end-to-end), Clinical and commercial supply chain for targeted radiotherapies, Isotope sourcing and supply agreements
Capacity assessment: 55.0/100
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press10 articles
Manufacturing site information being gathered
Modalities: Radiopharmaceutical CDMO (end-to-end), Clinical and commercial supply chain for targeted radiotherapies, Isotope sourcing and supply agreements
Capacity assessment: 55.0/100
Recent News 10 articles
Nucleus RadioPharma taps former FDA commissioner as CEO - Endpoints News
Nucleus RadioPharma: Building CDMO Sites to Ride the Radioligand Therapy Wave - Jonathan D. Grinstein, 2023 - Sage Journals
Radiopharma-Focused CDMO Nucleus Unveils Two New Plants, Looks to Create 100 Jobs - BioSpace
CDMO Nucleus RadioPharma Secures $50 Million Financing From OrbiMed to Expand Manufacturing Capacity - Pharmaceutical Online
Nucleus RadioPharma Secures $56 Million Series A Funding to Expand Production of Radiopharmaceutical Treatments for Cancer Patients - Business Wire
Nucleus RadioPharma to open manufacturing facility in Rochester, Minnesota - Mayo Clinic News Network
Nucleus RadioPharma taps former FDA head Stephen Hahn as chief executive - Fierce Pharma
Radiopharma CDMO Nucleus names former FDA boss as CEO - pharmaphorum
Nucleus RadioPharma Announces New Manufacturing Site In Mesa - Arizona Commerce Authority
Radiopharma CDMO Nucleus lays out plan to triple manufacturing capacity, add 100 jobs - Fierce Pharma
Frequently Asked Questions About Nucleus RadioPharma
What is Nucleus RadioPharma's CDMO Signal Score?
Nucleus RadioPharma has a Signal Score of 58/100, based on quality, operations, financial stability, and capacity data.
Evaluating Nucleus RadioPharma for a manufacturing program?
Use the free AI matchmaker to compare Nucleus RadioPharma against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.